SuperworthTransMedics EPS TMDX
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- $3.84
- Latest quarter, Q2 FY26
- $0.41
- −55% on a year earlier
- Fiscal year 2025
- $4.85
- +380% on the year before
TransMedics' earnings per share was $3.84 over the twelve months to Jun 30, 2026, up 99% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.41, down 55% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $4.85 | +380% |
| FY2024 | $1.01 | n/a |
| FY2023 | −$0.77 | n/a |
| FY2022 | −$1.25 | n/a |
| FY2021 | −$1.61 | n/a |
| FY2020 | −$1.20 | n/a |
| FY2019 | −$6.38 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.41 | −55% | $3.84 | |
| Q1 FY26 | $0.20 | −71% | $4.35 | |
| Q4 FY25 | $2.57 | +1253% | $4.85 | |
| Q3 FY25 | $0.66 | +450% | $2.47 | |
| Q2 FY25 | $0.92 | +163% | $1.93 | |
| Q1 FY25 | $0.70 | +100% | $1.36 | |
| Q4 FY24 | $0.19 | +58% | $1.01 | |
| Q3 FY24 | $0.12 | n/a | $0.94 | |
| Q2 FY24 | $0.35 | n/a | $0.04 | |
| Q1 FY24 | $0.35 | n/a | −$0.34 | |
| Q4 FY23 | $0.12 | n/a | −$0.77 | |
| Q3 FY23 | −$0.78 | n/a | −$1.10 |
Against its peers
Companies in Medical - Devices nearest TransMedics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TMDXTransMedics | $3.84 | +99% a year |
| CNMDCONMED | $1.85 | −48% a year |
| ITGRInteger | $3.66 | +61% a year |
| LIVNLivaNova | $3.39 | |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| Peer median | $3.52 |
Where TransMedics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on TransMedics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.